Compare Moderna, Inc. (MRNA) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sezzle Inc — how do they compare? Moderna, Inc. trades at $225.06 (market cap $78.65B), while Sezzle Inc trades at $127.04 (market cap $3.95B). The key difference: Moderna, Inc. is far larger — about 19.9× Sezzle Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Sezzle Inc for 15 Days on average.
| MRNA | SEZL | |
|---|---|---|
Market Cap | $78.65B | $3.95B |
Volume | 37,373,437 | 550,075 |
Sector | Health | Financials |
52-Week High | $203.46 | $188.55 |
52-Week Low | $22.36 | $50.97 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $74.80B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
SEZL stock trades at $126.61, up 11.21% with strong bullish momentum. The company demonstrates exceptional profitability with 30.35% net income margin and 88.85% ROE, supported by 51.7% revenue growth in Q2 2026. Technical indicators show bullish signals with current price above key support levels, while analyst consensus targets $168.00 representing 32.7% upside potential. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents compelling growth prospects with robust fundamentals and positive analyst sentiment, though elevated valuation multiples and competitive BNPL market dynamics warrant monitoring. The stock's current technical strength combined with strong earnings beats and institutional accumulation supports continued upside potential, while investors should consider the stock's premium valuation relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
